Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NEW YORK, Nov. 13, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) today reported financial results for the third quarter ended September 30, 2012. "Following a successful...
-
NEW YORK, Nov. 8, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that...
-
NDA Filing Expected to Occur in Fourth Quarter 2013 Company to Host Conference Call and Presentation Today, November 5, at 10:00 a.m. ET NEW YORK, Nov. 5, 2012 (GLOBE NEWSWIRE) -- Ventrus...
-
Ventrus Biosciences Appoints JP Benya Vice President, Commercial Operations and Business Development
NEW YORK, Sept. 24, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that...
-
NEW YORK, Aug. 29, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that...
-
NEW YORK, Aug. 9, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) today reported financial results for the second quarter ended June 30, 2012. "Following the announcement of the...
-
NEW YORK, June 25, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS) today reported that its Phase 3, randomized, double-blind, placebo-controlled clinical trial of iferanserin (VEN...
-
NEW YORK, May 30, 2012 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced today that...
-
NEW YORK, May 15, 2012 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced today that...
-
Treatment Arms Show Significant Improvement Over Placebo in Three Major Outcomes Adverse Events Similar Between Treatment Arms and Placebo Company to Host Conference Call and Presentation...